CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 291 enrolled
Drug / intervention
RF energy delivery for treatment of Typical Atrial flutterdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00318565
NCT00318565Phase 4Completed
CompareCT.gov

Navistar Thermocool Evaluation of the Catheter With the Stockert 70 Radiofrequency Generator for Endocardial Ablation in Patients With Typical Atrial Flutter

Biosense Webster, Inc.·interventional·Posted Apr 27, 2006·Updated Mar 5, 2012

In Brief

A Phase 4 clinical trial evaluating RF energy delivery for treatment of Typical Atrial flutter for Atrial Flutter. Completed, enrolled 291 participants across 23 sites.

Detailed Summary

The primary objective is to provide additional corroborative safety and efficacy data for the Navistar Thermocool catheter for the treatment of subjects with typical atrial flutter (AFL).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Flutter
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 27, 2006
Enrollment StartJan 1, 2006
Primary CompletionSep 1, 2007
Study CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 20.2 years ago

Interventions

RF energy delivery for treatment of Typical Atrial flutterdevice

Navistar ThermoCool catheter